Detailed narrative
Q2 Performance Highlights
Alphatec Holdings reported total revenue of $214 million in Q2 FY26, marking a 15% increase year-over-year, with surgical revenue growing 17%. This robust performance was primarily driven by a 24% increase in surgical adoption and a 20% rise in procedural volume, indicating strong market penetration and utilization. Adjusted EBITDA reached $36 million, up 53% year-over-year, with a 17% margin, demonstrating significant operating leverage and scalability.
EOS Strategy and Impact
EOS revenue contributed $17 million in Q2. The company emphasized EOS as a foundational clinical tool that provides access to prestigious academic institutions and influences future surgeon adoption. Notably, EOS Insight has shown to increase implant revenue by approximately 32% within six months of adoption in established accounts, highlighting its strategic value in enhancing surgeon engagement and driving long-term growth. The penetration rate of EOS Insight into the installed base is currently 15-20%.
Clinical Distinction and Procedural Approach
Alphatec's strategy centers on creating clinical distinction by integrating products into comprehensive procedural solutions rather than focusing on individual implants. This approach, particularly in lateral surgery with advancements like SAFOP and Valence, aims to build surgeon confidence and expand utilization across complex pathologies. This philosophy is also extending to other procedures such as cervical and posterior fixation, leading to compounding surgeon utilization.
Valence and SafeOp Integration
Valence, the company's navigation platform, is being strategically integrated into the operating room workflow, with recent FDA clearances for IOA (interoperative alignment) and Contour 3D, an automated rod bender. SafeOp plays a critical role by providing real-time neural intelligence. These technologies form an integrated ecosystem designed to deepen surgeon confidence and establish Alphatec as an essential partner in surgical execution.
International Growth and Deformity
The company's clinical distinction model is successfully being replicated in international markets, including Japan, Australia, and New Zealand, expanding its global opportunity. Additionally, Alphatec is growing its influence in complex deformity procedures, leveraging its EOS imaging, alignment data, bone marrow density assessment, and patient-specific planning capabilities to support surgeons in challenging cases.
Gross Margin Expansion and Operating Discipline
Gross margin improved by 260 basis points year-over-year to 72.5%, driven by enhanced inventory efficiency, cost reductions, and a favorable product mix. Operating expenses grew 11% but improved by approximately 260 basis points as a percentage of revenue, reflecting disciplined reinvestment and strong operating leverage that translates revenue growth into expanding profitability.
Balance Sheet and Cash Flow
Alphatec ended the quarter with a strong liquidity position, including $119 million in cash and $85 million in available borrowing capacity, totaling $204 million. The company generated $34 million in operating cash flow and $1 million in positive free cash flow, surpassing its break-even expectation. A new term loan A and revolving credit facility were completed, extending maturities to 2031 and reducing annual interest expense by over $6 million.